Edition:
United Kingdom

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

2.56USD
5:20pm BST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.56
Open
$2.55
Day's High
$2.61
Day's Low
$2.55
Volume
8,632
Avg. Vol
8,816
52-wk High
$3.64
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

Pernix Therapeutics Reports Result Of Bid Process For Acquisition Of Worldwide Rights To Contrave
Friday, 22 Jun 2018 

June 22 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES RESULT OF BID PROCESS FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS.NALPROPION PHARMACEUTICALS INFORMED BY OREXIGEN THERAPEUTICS NO OTHER BIDS FOR OREXIGEN'S ASSETS GOT BY COURT-APPROVED BID DEADLINE.NALPROPION ANTICIPATES BEING DECLARED HIGHEST, BEST BIDDER FOR ASSETS AND CLOSING ON DEAL BY JULY 13, 2018.  Full Article

Orexigen Therapeutics Enters Agreement For Sale Of Co
Monday, 23 Apr 2018 

April 23 (Reuters) - Orexigen Therapeutics Inc ::OREXIGEN THERAPEUTICS, INC. ENTERS AGREEMENT FOR SALE OF COMPANY.OREXIGEN THERAPEUTICS INC - ENTERED INTO ASSET PURCHASE DEAL WITH NALPROPION PHARMACEUTICALS, TO SELL SUBSTANTIALLY ALL OF ASSETS OF CO.OREXIGEN THERAPEUTICS INC - WILL SELL WORLD-WIDE RIGHTS TO CONTRAVE /MYSIMBA AND CERTAIN OTHER OREXIGEN ASSETS FOR $75 MILLION IN CASH.OREXIGEN THERAPEUTICS- NALPROPION PHARMACEUTICALS IS A NEWLY FORMED SPECIAL PURPOSE ENTITY CAPITALIZED BY INVESTOR GROUP INCLUDING PERNIX THERAPEUTICS.  Full Article

Pernix Therapeutics Announces Participation In Lead Bid Worldwide Rights Of Contrave
Monday, 23 Apr 2018 

April 23 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES PARTICIPATION IN LEAD BID FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS.PERNIX THERAPEUTICS HOLDINGS - TO PARTICIPATE IN INVESTOR GROUP THAT ENTERED INTO "STALKING HORSE" ASSET PURCHASE DEAL TO ACQUIRE SOME ASSETS OF OREXIGEN THERAPEUTICS.PERNIX THERAPEUTICS HOLDINGS - WOULD CONTRIBUTE 10% OF CAPITAL REQUIRED TO FUND PURCHASE PRICE OF DEAL, OR $7.5 MILLION.PERNIX THERAPEUTICS - WOULD CONTRIBUTE 10% OF CAPITAL REQUIRED TO FUND PURCHASE PRICE, OR $7.5 MILLION, FUNDED THROUGH DRAW UNDER EXISTING DELAYED DRAW TERM LOAN FACILITY.  Full Article

Pernix Therapeutics Will Reduce Workforce By 41 Employees
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS HOLDINGS INC - WILL REDUCE WORKFORCE BY 41 EMPLOYEES; MAJORITY EXPECTED TO BE WITH CO'S SALES FORCE & COMMERCIAL INFRASTRUCTURE.PERNIX THERAPEUTICS - ‍EXPECTS TO COMPLETE REALIGNMENT PLAN TO REDUCE OPERATING COSTS, ALIGN WORKFORCE ON JAN 5, 2018 - SEC FILING​.  Full Article

Pernix Therapeutics files for mixed shelf offering of up to $150 mln
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Pernix Therapeutics Holdings Inc ::Pernix Therapeutics Holdings files for mixed shelf offering of up to $150 million - SEC filing‍​.  Full Article

Pernix Therapeutics posts Q3 revenue of $40.5 mln
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Pernix Therapeutics Holdings Inc :Pernix Therapeutics reports third quarter 2017 financial results.Q3 revenue fell 2 percent to $40.5 million.  Full Article

Pernix Therapeutics announces sale of non-core product
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Pernix Therapeutics Holdings Inc :Pernix Therapeutics announces sale of non-core product.Pernix Therapeutics Holdings Inc - ‍sale of a non-core product Cedax to SI Pharmaceuticals LLC, for $2 million in gross cash proceeds​.  Full Article

Pernix reports reverse stock split and corporate governance enhancements
Thursday, 13 Oct 2016 

Pernix Therapeutics Holdings Inc : Pernix Therapeutics announces reverse stock split and corporate governance enhancements . Pernix Therapeutics Holdings Inc - trading on post-split basis on nasdaq commencing at open of stock market on October 14, 2016 .Pernix Therapeutics Holdings Inc- board of directors unanimously approved a reverse split of its common stock at a ratio of 1-for-10.  Full Article

Pernix Therapeutics qtrly net loss per common share $0.47
Thursday, 11 Aug 2016 

Pernix Therapeutics Holdings Inc : Pernix therapeutics reports second quarter 2016 financial results and business update . Pernix therapeutics holdings inc q2 revenue $36.7 mln vs i/b/e/s view $40.3 mln .Pernix therapeutics holdings inc qtrly net loss per common and potential common share $0.47.  Full Article